C-peptide is gaining much interest recently due to its well-documented beneficial effects on multiple organ dysfunction induced by diabetes. Our study was designed to investigate the effect of C-peptide on hepatocellular dysfunction in diabetic rats. Wistar male rats were separated into four groups: control, diabetic, diabetic + insulin, and diabetic + C-peptide. Serum levels of glucose, insulin, and liver biomarkers were assessed. Liver sections were collected for histopathological examination and immuno-histochemical assessment of tumor necrosis factor alpha (TNF-α). Oxidative stress markers and gene expression of inducible nitric oxide synthase (iNOS), transforming growth factor beta 1 (TGF-β1), and glucose-6-phosphatase (G6Pase) were also measured in liver tissues. C-peptide administration prevented hepatic dysfunction induced by diabetes to a similar extent as that of insulin which was confirmed microscopically. We concluded that C-peptide could be used as an alternative therapy to insulin to correct hepatocellular dysfunction associated with type 1 diabetes mellitus (T1DM).

中文翻译：

---

C肽可纠正1型糖尿病大鼠模型中的肝细胞功能障碍。

由于C肽对糖尿病引起的多器官功能障碍的有益作用，最近C肽引起了人们极大的兴趣。我们的研究旨在研究C肽对糖尿病大鼠肝细胞功能障碍的影响。将Wistar雄性大鼠分为四组：对照组，糖尿病，糖尿病+胰岛素和糖尿病+ C肽。评估血清葡萄糖，胰岛素和肝脏生物标志物的水平。收集肝切片用于肿瘤坏死因子α（TNF-α）的组织病理学检查和免疫组织化学评估。还测量了肝脏组织中氧化应激标志物和诱导型一氧化氮合酶（iNOS），转化生长因子β1（TGF-β1）和葡萄糖-6-磷酸酶（G6Pase）的基因表达。给予C肽可预防糖尿病引起的肝功能异常，其程度与经显微镜证实的胰岛素相似。我们得出的结论是，C肽可用作胰岛素的替代疗法，以纠正与1型糖尿病（T1DM）相关的肝细胞功能障碍。